CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that data from the company’s tivozanib and AV-299 (SCH 900105) programs will be featured in several poster sessions at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting being held June 4-8, 2010, in Chicago.
